Title

Phase II trial of BB-10901 (huN901-DM1) given weekly for four consecutive weeks every 6 weeks in patients with relapsed SCLC and CD56-positive small cell carcinoma

Author Department

Medicine

Document Type

Presentations, Research

Publication Date

5-1-2005

Share

COinS